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ABO serology in a case of persistent weak A 
in a recipient following a group O–matched 
unrelated bone marrow transplant
D.E. Grey, E.A. Fong, C. Cole, J. Jensen, and J. Finlayson
Case RepoRt
HLA-matched hematopoietic stem cell transplantation (HSCT) 
from red blood cell (RBC)-incompatible donors is not uncommon. 
The engraftment process following ABO-incompatible allogeneic 
HSCT results in the transition from patient blood group to donor 
blood group in the recipient. In contrast, most non-hematopoietic 
tissues retain expression of the patient’s original blood group for 
life, and these antigens may adsorb from the plasma onto the 
donor-derived RBCs. Correct serologic interpretation of the ABO 
blood group during this engraftment process can be difficult. 
We present the serologic findings of a 15-year-old girl of Maori 
descent, who was diagnosed with acute myeloid leukemia and 
transplanted with an HLA-matched unrelated group O, D+ bone 
marrow. Despite engraftment, her RBCs showed persistence of 
weak A. This case report showcases the importance of awareness 
and correct serologic interpretation of weak persistence of 
recipient ABH substance on the patient’s RBCs for clinical 
decision-making, blood component support, and patient well-
being. Immunohematology 2017;33:99–104.
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HLA-matched hematopoietic stem cell transplantation 
(HSCT) from red blood cell (RBC)-incompatible donors is 
not uncommon.1 ABO-incompatible HSCT is of particular 
importance because of the consequences of acute hemolysis 
and the complexity of blood component selection.
ABO antigens and the closely related H, secretor, and 
Lewis histo-blood group carbohydrates are synthesized 
by specific glycosyltransferases encoded by ABO, FUT1, 
FUT2, and FUT3, respectively. These enzymes incorporate 
monosaccharide units into precursor oligosaccharide chains, 
modifying them and creating new antigenic specificities.2 
FUT1 and ABO encode enzymes that synthesize H, A, and B 
in mesodermal and hematopoietic tissues that are therefore 
intrinsic to the RBC. FUT2 and FUT3, together with ABO, are 
responsible for H, A, B, Lea, Leb, ALeb, and BLeb carbohydrates 
on ectodermal tissues such as the gut, respiratory and urinary 
mucosae, and exocrine secretions, which are transported to 
the plasma and adsorbed onto the RBC membrane.2–4
The engraftment process following ABO-incompatible 
allogeneic HSCT results in the transition from patient blood 
group to donor blood group in the recipient. In contrast, most 
non-hematopoietic tissues retain expression of the patient’s 
original blood group for life, and these antigens may adsorb 
from the plasma onto the donor-derived RBCs.5
The correct serologic interpretation of the recipient’s 
ABO blood group during this engraftment process can be 
difficult because of serologic discrepancies caused by ABO 
incompatibility between the recipient and donor during 
engraftment, transfusion of blood components with differing 
ABO group to the recipient, administration of high-dose 
intravenous immunoglobulin producing elevated levels of ABO 
isoagglutinins, engraftment failure, and relapse. In addition, 
adsorption of recipient antigens onto donor RBCs adds another 
level of complexity to the interpretation of the ABO group, and 
this may have implications for blood component support and 
clinical decision-making.
We present the serologic findings of a case of persistent 
weak A in a recipient following a group O HLA-matched 
unrelated bone marrow transplant.
Case Report
A 15-year-old girl of Maori descent was diagnosed with 
acute myeloid leukemia in 2014. Her RBCs typed as group A, 
D+, Le(a–b–). A total of 46 units of group A, D+ RBCs and 
64 units of group A and 2 units of group O apheresis platelets 
were transfused during the first 5 months following diagnosis. 
The patient was then transplanted with an HLA-matched 
unrelated group O, D+ bone marrow. A further 7 units of 
RBCs, all group O, D+, and 18 group A and 4 group O units 
of apheresis platelets were transfused post-transplant, within 
a 1-month period. There were no units of RBCs or platelets 
transfused during the following 27 months.
Engraftment was confirmed by day 24 post-transplant 
with short tandem repeat chimerism studies (lymphocytes) 
showing 99 percent chimerism (Table 1).
Five months post-transplant, routine blood grouping 
(BioVue column agglutination technology [CAT]; Ortho 
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Clinical Diagnostics, Bridgend, UK) showed weak reactivity of 
patient RBCs with monoclonal anti-A; anti-B was detectable in 
the reverse group. These weak reactions persisted throughout 
the 28-month post-transplant review period. At the time of 
last review, the full blood count and renal and liver function 
indices were all normal.
Materials and Methods
Patient Blood Typing
ABO and D typings were performed using commercially 
available reagents according to the manufacturer’s protocols 
by conventional tube test (CTT), as well as by CAT (BioVue 
CAT, Ortho Clinical Diagnostics, and Bio-Rad CAT, Bio-Rad 
Laboratories, DiaMed GmbH, Cressier, Switzerland). The 
patient’s RBCs were also tested using a lectin (Anti-H lectin, 
Ulex europaeus; Seqirus, Victoria, Australia) and monoclonal 
antibodies (Epiclone Anti-Lea and Anti-Leb; Seqirus). The 
ABO antisera clones are shown in Table 2. Patient and control 
RBCs (Securacell; Seqirus) were treated with papain (Papain 
Solution; Seqirus), and the forward ABO typing was tested 
by Bio-Rad CAT (DiaClon ABO/Rh for Newborns; Bio-Rad 
Laboratories).
Papain-treated and -untreated patient RBCs were also 
tested against two group O plasma samples with known anti-A 
titers of 256 and 512, respectively, and read at antiglobulin 
phase (Anti-IgG-C3d; Bio-Rad CAT, Bio-Rad Laboratories).
Adsorption-Elution Studies
Adsorption-elution studies were undertaken to confirm 
the presence of A using one volume of papain-treated patient 
RBCs incubated at room temperature for 1 hour with 1 
volume of anti-A containing Birma-1 (Gamma-Clone Anti-A; 
Immucor, Norcross, GA), anti-B using B9 (Epiclone Anti-B; 
Seqirus), and a blended anti-A,B using 4E7, B9, and ES15 
(Epiclone Anti-A,B; Seqirus).6 A rapid acid elution was then 
performed in accordance with the manufacturer’s instructions 
(DiaCidel; Bio-Rad Laboratories). The eluate and last wash 
were incubated for 10 minutes at room temperature with 
commercial A1, B, and O cells (Seqirus) using the CAT card 
(ID-card NaCl, enzyme test, and cold agglutinins; Bio-
Rad Laboratories). Controls were run using A1 and O RBCs 
(Seqirus).
All agglutination reactions, negative to positive, were 
graded as 0 to 4+, respectively.
Results
ABO and D Typings
Table 1 shows the results of the patient’s ABO and D 
typings by CAT (BioVue) at different time points. At diagnosis, 
the patient’s RBCs typed as group A, D+, with strong 
agglutination (4+) with monoclonal anti-A (BioVue CAT). 
Nine days post-transplant, mixed-field agglutination with 
anti-A (BioVue CAT) was observed, consistent with the recent 
transfusion of 2 group O, D+ RBC units.
By day 24 post-transplant, engraftment was confirmed 
with the short tandem repeat chimerism studies (lymphocytes) 
showing 99 percent donor detectable (Table 2).
Five months post-transplant, the patient’s RBCs showed 
weak agglutination (1+) with A sera (monoclonal Anti-A; 
BioVue CAT, Ortho Clinical Diagnostics) while the patient’s 
plasma reacted only with B cells (Seqirus) (3+). There was 
no evidence of mixed-field agglutination at this time. The last 
transfusion had occurred 4 months prior.
The patient’s blood type was reviewed at 28 months 
post-transplant, at which point the weak reactivity (1+) of 
the patient’s RBCs with monoclonal reagent (monoclonal 
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Table 1. Results of patient ABO and D blood typing by CAT (BioVue, Ortho Clinical Diagnostics, Bridgend, UK; agglutination grade 0–4+) 
and short tandem repeat lymphocytes chimerism studies at diagnosis and at different time points post-transplant
Anti-A Anti-B Anti-A,B Anti-D Anti-H A1 Cells B Cells STC (%)









At diagnosis 4+ 0 nt 4+ nt 0 4+ nt
Day 9 mf 0 nt 4+ nt 0 3+ nt
Day 24 nt nt nt nt nt nt nt 99
3 months nt nt nt nt nt nt nt 99
5 months 1+ 0 nt 4+ nt 0 3+ 99
8 months nt nt nt nt nt nt nt 98
9 months 2+ 0 nt 4+ nt 0 3+ nt
28 months 1+ 0 2+ 4+ 4+ 0 2+ nt
mf = mixed field; nt = not tested; STC = short tandem repeat lymphocytes chimerism.
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ABO serology of weak A post-HSCT
Anti-A; BioVue CAT, Ortho Clinical Diagnostics) remained 
(Fig. 1A). Agglutination of the patient’s RBCs with MH04, 
3D3, NB10.5A5, NB1.19 clones (monoclonal anti-A,B; BioVue 
CAT, Ortho Clinical Diagnostics), although still weak, was 
stronger (2+) than that observed with the MH04, 3D3 clones 
(monoclonal Anti-A; BioVue CAT, Ortho Clinical Diagnostics) 
(Fig. 1). In contrast, there was no agglutination with anti-A 
LM297/628 (LA-2) clones (DiaClon ABO/Rh for Newborns; 
Bio-Rad CAT, Bio-Rad Laboratories) and very weak 
agglutination (<1+) with anti-A,B ES131 (ES-15), BIRMA-1, 
ES-4 clones (DiaClon ABO/Rh for Newborns; Bio-Rad CAT, 
Bio-Rad Laboratories) (Fig. 2A). Reactivity, following papain 
treatment of the patient’s RBCs, was observed with anti-A (2+ 
to 3+) and enhanced with anti-A,B (3+ to 4+) (both DiaClon 
ABO/Rh for Newborns; Bio-Rad CAT, Bio-Rad Laboratories) 
(Fig. 2B). Papain-treated commercial A1, A2, Awk, B, and O 
RBCs (Seqirus) were included as controls for the Bio-Rad CAT 
(Bio-Rad Laboratories); there was no false-positive or false-
negative agglutination.
When CTT typing was performed, there was no 
agglutination using two different A sera (4E7, 8F2, Epiclone 
Anti-A, Seqirus, and Birma-1 Gamma-Clone Anti-A, 
Immucor), although weak agglutination (1+) was observed 
with AB clones 4E7, B9, and ES15 (Epiclone Anti-A,B; Seqirus).
Group O plasma with an anti-A titer of 512 agglutinated 
both untreated (2+) and papain-treated (3+ to 4+) patient 
RBCs. In contrast, the group O plasma with an anti-A titer of 
256 only agglutinated papain-treated (2+) patient RBCs and 
not the untreated sample.
Adsorption-Elution Studies
BIRMA-1 (Gamma-Clone Anti-A; Immucor) and 4E7, 
B9, and ES15 (Epiclone Anti-A,B; Seqirus) were detectable in 
the eluate with A1 cells following adsorption-elution studies 
(4+), and the absence of mixed-field reactivity confirmed the 
presence of A only on the patient’s RBCs. Eluates prepared 
from anti-A– or anti-A,B–adsorbed RBCs were not reactive 
with commercial B or O cells (Seqirus). Monoclonal anti-B 
was not detectable in the eluate, and there were no antibodies 
demonstrable in the final wash.
Table 2. Antisera clones for each of the ABO monoclonal 
antibodies used
Anti-A Anti-B Anti-A,B














CTT (Epiclone, Seqirus) 4E7, 8F2 B9 4E7, B9, ES15
Highlighting indicates the directly agglutinating clones.
Fig. 1 Results of patient’s ABO typing, forward and reverse, and D typing using CAT (BioVue; Ortho Clinical Diagnostics, Bridgend, UK) 
showing a weak reaction with monoclonal anti-A (A) and the comparative difference in reaction strength with monoclonal anti-A,B (B). ctrl 
= control.
102 IMMUNOHEMATOLOGY, Volume 33, Number 3, 2017
Discussion
A compromise in ABO compatibility is often required to 
satisfy the most important predictor of allogeneic matched 
unrelated HSCT outcome—namely, the HLA match between 
donor and recipient.7 As a consequence, difficulties can arise 
in ABO interpretation.
One area of ABO-incompatible HSCT that has received 
minimal attention, for which there is limited serologic 
information, is that of the weak persistence of recipient ABH 
substance.5,8–12
In the case we describe, the patient’s RBCs consistently 
showed weak agglutination with A and A,B sera (monoclonal 
Anti-A and Anti-A,B; BioVue CAT; Ortho Clinical Diagnostics) 
up to 28 months after the group O transplant; the reaction 
strength with anti-A,B was stronger than that with anti-A. 
Although other anti-A,B clones were also reactive by different 
methods, other monoclonal A reagents were not. This 
pattern of reactivity is similar to that described for the ABO 
subgroup Ax, where very low levels of A are agglutinated by 
the majority of group O sera, but by only a few group B sera.13 
This phenomenon was thought to be a result of the higher 
association constant found with immune anti-A,B in group O 
sera compared with anti-A in group B sera.14
Two clones, ES-15 and MH04, which were present in 
the antisera showing persistent weak agglutination with the 
patient’s RBCs post-transplant, have been reported to detect 
low levels of A expression.15,16 As an antisera, clone ES-15 has 
been reported to agglutinate 95 percent of Ax examples15; the 
BIRMA-1 clone agglutinated only 60 percent.17 MH04, although 
able to detect weak subgroups of A including Ax, has been 
associated with false-positive reactions in 1 percent of group 
B donors. These donors, termed B(A), were shown to exhibit 
high levels of B-gene–specified transferase activity resulting 
in the transfer of small amounts of N-acetyl-d-galactosamine 
(A-active structures) to H-active structures on group B 
RBCs.16 As a consequence of this finding, recommendations 
were made that monoclonal A reagents should not detect the 
so-called B(A) phenomenon. It was considered desirable, but 
not essential, for the monoclonal A reagents to react with 
RBCs expressing very low levels of A, including Ax and Ah, but 
essential for monoclonal anti-A,B reagents to do so.18
It is interesting to speculate further as to why the reaction 
strength with A,B sera was stronger than with the A sera 
(BioClone Anti-A and Anti-A,B; BioVue CAT; Ortho Clinical 
Diagnostics) when the clones for A,B sera (which include 
MH04) were a blend of the A and B clones. This difference in 
reaction strength does not fit the concept of a higher association 
constant as described for human anti-A,B in group O sera.14 
Perhaps the potency of MH04 has simply been reduced to 
overcome the B(A) phenomenon.
Although monoclonal antibody specificity is important 
in the detection of persistent weak A expression, we cannot 
exclude the role of macromolecular potentiators, present in the 
one CAT system (BioVue) to enhance the antigen–antibody 
reactions. In the ABO setting, papain treatment of RBCs is 
also known to enhance antigen–antibody reactions through 
removal of glycoproteins from the surface layer, with resultant 
reduction of steric repulsion and a 40 percent decrease in 
surface charge density.19,20 In the case we describe, papain 
treatment of the patient’s RBCs confirmed the presence of A, 
enabling direct agglutination with a monoclonal anti-A that 
had not been agglutinable.
Garratty et al.12 studied the RBCs from an A1 patient 
expressing weak A reactivity 5 months after receiving a group 
O bone marrow transplant using flow cytometry and found 
that there was a single right-shifted population. In contrast, 
chimeric or mixed-field RBCs showed two distinct populations. 
We, too, found no evidence of mixed-field agglutination either 
D.E. Grey et al.
Fig. 2 Results of ABO forward type, D type, and direct antiglobulin 
test (DAT) with untreated patient’s red blood cells (RBCs) using 
CAT (Bio-Rad Laboratories, DiaMed GmbH, Cressier, Switzerland) 
(A) compared with papain-treated patient RBCs (B). ctl = control.
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by CTT or CAT, consistent with weak recipient A substance 
adsorbed onto the RBCs from the plasma. The concept that 
group O RBCs can acquire weak A or B was initially described 
in 1962, when Renton and Hancock21 observed that group O 
RBCs, which had been emergently transfused into group A 
or B recipients, produced “loose stringy” agglutination when 
reacted with group O sera. It was later found that the amount 
of A in lipid fractions isolated from the serum of group A 
donors was highest from group A1 Le(a–b–) secretors.22 Needs 
et al.8 also ascertained the importance of secretor status when 
they observed “small quantities” of recipient ABH substance 
on post-transplant RBCs when the recipient was a secretor but 
not when the recipient was a non-secretor.
It is known that 80 percent of Le(a–b–) individuals and 
all Le(a–b+) individuals are ABH secretors, and all Le(a+b–) 
individuals are ABH non-secretors.23 It is of interest that 
Henry et al.24 found that glycolipid fractions prepared from the 
plasma and RBCs of selected Polynesian samples (including 
Maoris) of RBC Le(a–b–), Le(a+b–), and Le(a+b+) phenotypes 
were found to have Leb glycolipids, suggesting that the 
recessive non-secretor gene is absent or rare in a Polynesian-
derived gene pool. In our case the patient’s RBCs typed as 
Le(a–b–). Although we recognize that the Lewis phenotype 
can be misleading in certain physiological and disease states,25 
it is likely that our patient was a secretor, and this assumption 
is consistent with the persistent presence of recipient A on the 
patient’s RBCs.
One limitation of our study is that we did not measure 
the level of soluble recipient ABH in the patient’s plasma. 
In a recent study by Hult et al.,5 flow cytometric analysis 
confirmed the major role of A/B adsorption from secretor 
plasma; an additional, secretor-independent mechanism for 
A/B acquisition was also indicated.
Available evidence suggests that persistence of weak 
recipient ABH substance is not associated with relapse.10 In 
the experience of De Vooght et al.,10 patients expressed concern 
that when this phenomenon was exhibited, it represented 
an unsuccessful transplant or relapse that then created 
unnecessary anxiety that affected the patient’s quality of life.
The decision to switch a patient’s blood group following 
ABO-incompatible HSCT is complex and varies across 
institutions.7 Major or minor ABO mismatches, engraftment, 
relapse, and transfusion dependence all affect the decision. In 
addition, adsorption of recipient antigens onto donor RBCs 
adds another level of complexity to the interpretation of the 
recipient’s ABO group.
The phenomenon of recipient weak ABH substance on the 
patient’s RBCs may affect the choice of ABO group for blood 
component transfusion support in patients undergoing HSCT. 
For RBC transfusions, the ABO group of the components should 
be compatible with both the recipient and donor following 
HSCT, and then the components should be switched to the 
donor group following engraftment. It is now recommended, 
however, that platelet and plasma components remain ABO-
compatible with both the recipient and donor for life.5,26
In conclusion, the awareness and correct serologic 
interpretation of recipient weak ABH substance on a patient’s 
RBCs is important for clinical decision-making, blood 
component support, and patient well-being.
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